An editorial in The Oregonian mentions OHSU offers training to nurse practitioners, physician assistants and others on providing abortions and other reproductive health services.

OHSU's John Hunter, M.D., discusses the expense of hiring travel nurses throughout the pandemic.

Researchers from OHSU and Oregon State University collaborate on promising new treatment for pancreatic cancer. Brett Sheppard, M.D., says: "It not only gives me hope, but I hope that it gives patients and their families hope, because we've made a lot of progress."

In a presentation at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting regarding the impact COVID-19 vaccines on fertility and pregnancy, Alison Edelman, M.D., says: "We have all been bombarded with information and misinformation over the last several years, not to mention the weariness and burnout in providing care during a pandemic; as such, we designed this presentation to provide a useful and practical summary of this evidence to our colleagues at ACOG, in order to help them better care for their patients and address their concerns."

Four OHSU startup companies -- CytoImage, Inherent Targeting, Center M Inc., and Auxetics -- discuss their precision medicine, imaging, perinatal depression prevention and stent design technologies at OHSU’s annual Innovation Day event.

New research led by Ov Slayden, Ph.D., and Oleh Taratula, Ph.D., suggests nanoparticle technology could be new, noninvasive treatment for endometriosis.

Research led by Jeni Johnstone, Ph.D., suggesting vitamins, minerals improve symptoms in children with ADHD, continues to drive media interest.

Maria Rodriguez, M.D., discusses abortion options, logistics: "It's a health condition, people are stressed, and then they're having to add in all these logistics of financial concerns as well as logistical concerns about travel. It's a lot. It's a lot to go through, and it's a lot of support people need."

OHSU will pay a $1 million settlement in response to a lawsuit regarding the death of a patient with cancer. OHSU statement: "OHSU extends its sincere condolences to the family and friends of Mr. McIntyre. As a community of healers devoted to advancing health, the passing of a patient, under any circumstances, is devastating to all involved. Patient privacy laws prevent us from disclosing protected health information; however, we want to share the following: • OHSU has followed, and continues to follow, national cancer guidelines and evidence-based medicine set forth by national expert consensus in the field. • National treatment guidelines established by the major cancer societies in the U.S. do not recommend DPD, or dihydropyrimidine dehydrogenase, testing prior to starting chemotherapy. • Although DPD testing is not part of the standard of care for delivering chemotherapy, OHSU is enhancing its educational component on DPD deficiency in its Oncology Fellowship program. • OHSU also plans to create a Resource Guide that describes DPD deficiency, how it relates to metabolism of capecitabine and what to look for in relationship to early-onset symptoms -- this Resource Guide will be available to everyone in the oncology department."

Paul Yang, M.D., says 18 months of data from a Phase 1/2 clinical trial of an experimental gene therapy for X-linked retinitis pigmentosa, a rare cause of blindness for which there is no approved treatment, “indicate sustained durability of improved visional function."